Frequency Therapeutics reports trial fail and lays off over half of staff — stock capsizes

Frequency Therapeutics announced Monday morning that its lead candidate, a drug for hearing loss, failed a Phase IIb study. As a result, the Lexington, MA-based biotech will discontinue its hearing loss program and lay off 55% of its staff.